Proactive Investors - Run By Investors For Investors

Midatech ups sales hopes; brain cancer treatment chosen for human trials

The firm also updated the market on its financial progress
Midatech ups sales hopes; brain cancer treatment chosen for human trials
The Bristol Royal Infirmary has chosen Midatech’s glioblastoma treatment


Fast growing drug delivery group Midatech’s (LON:MTPH, NASDAQ:MTP)  pleased the market with an upgraded revenue forecast, as its paediatric brain tumour treatment was chosen for a programme by the Bristol Royal Infirmary.

The hospital has chosen Midatech’s glioblastoma treatment for its compassionate use programme to deliver an active therapeutic agent to a rare paediatric brain tumour.

Panmure Gordon said: “It signifies what we consider to represent a potential acceleration of the company’s programmes in brain cancer, notably in young children."

These highly aggressive and difficult-to-treat tumours are found at the base of the brain and occur almost exclusively in children.

“While this is a single programme for a rare disease it brings forward the in-human trials of the Midatech cancer therapeutic products very significantly,” the company said.

Panmure added: “We consider this a strong validation of Midatech’s platform and, if successful, could result in a fasttracked product to market where there is currently an unmet clinical need."

The firm also updated the market on its financial progress, which, as a result of recent acquisitions of oncology specialists DARA Biosciences and Zuplenz, shows sales will be ahead of market hopes.

Panmure Gordon said the news “helps to reaffirm our view on trading,” as it upped its full-year revenue expectations to £1.3mln from £1.2mln.

“In light of the confident trading update, the accelerated in-human application of the company’s technology in oncology and the, in our view, unjustified current share-price levels, we regard Midatech as a compelling investment,” the broker added.

Shares in the firm rocketed by lunch, up 15% to 205p.

Why Invest In Midatech Pharma Plc? Read More Here

Register here to be notified of future MTPH Company articles
View full MTPH profile

Midatech Pharma Plc Timeline

Related Articles

April 13 2016
Jim Phillips, Midatech’s chief executive, said Zuplenz offers relief from some of the most debilitating side-effects of common cancer treatments. Generically called ondansetron, the oral soluble film eases the problem of gritty residue, having to wear a patch and sedative side effects of dissolving tablets and injections.
March 31 2016
Amryt Pharmaceuticals is coming to the market following a reverse takeover deal with the investment firm Fastnet Equities. Here boss Joseph Wiley tells us a little bit more about the AIM newcomer.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.